Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

Abstract

BackgroundTo analyze and compare the economic outcomes of adjuvant chemotherapy with capecitabine plus oxaliplatin (referred to as the XELOX strategy) and of S-1 (the S-1 strategy) for gastric cancer patients after D2 gastrectomy.MethodsA Markov model was developed to simulate the lifetime disease course associated with stage II or III gastric cancer after D2 gastrectomy. The lifetime quality-adjusted life years (QALYs), associated costs, and incremental cost-effectiveness ratios (ICERs) were estimated. The clinical data were derived from the results of pilot studies. Direct costs were estimated from the perspective of the Chinese healthcare system, and the utility data were measured from end-point observations of Chinese patients. Sensitivity analyses were used to explore the impact of uncertainty on the model’s outcomes.ResultsThe combined adjuvant chemotherapy strategy with XELOX yielded the greatest increase in QALYs over the course of the disease (8.1 QALYs compared with 7.8 QALYs for the S-1 strategy and 6.2 for surgery alone). The incremental cost per QALY gained using the XELOX strategy was significantly lower than that for the S-1 strategy ($3,502 vs. $6,837, respectively). The results were sensitive to the costs of oxaliplatin and the hazard ratio of relapse-free survival.ConclusionThe observations reported herein suggest that adjuvant therapy with capecitabine plus oxaliplatin is a highly cost-effective strategy and more favorable treatment option than the S-1 strategy in patients with stage II or III gastric cancer who have undergone D2 gastrectomy.

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

“…The general Weibull equation is as follows (in which 't' is time in months): S(t) = e − t . Lambda and gamma parameters of the patients treated with chemotherapy in the EURTAC trial were used to estimate the parameters for gefitinib, erlotinib, afatinib, and osimertinib, as previously described in published studies [36,37]. For example, the lambda parameter (scale parameter) for gefitinib was estimated by multiplying the lambda for chemotherapy by the pooled HR of gefitinib versus chemotherapy.…”

Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis

“…Other costs were obtained from previously published studies [25,26]. All costs are reported in 2018 US dollars.…”

Economic Analysis of ALK Testing and Crizotinib Therapy for Advanced Non-Small-Cell Lung Cancer

“…Following disease progression, salvage chemotherapy and supportive care would be prescribed and 56.6% (26-72%) of patients would receive salvage treatment regardless of the first-line therapy [31][32][33][34][35][36]. The resource utilization related to salvage chemotherapies and supportive care was derived from a previously published study [28]. In addition, the current analysis also included the cost of palliative end-of-life care, which was derived from a survey that included 727 patients with advanced cancer who received hospice care in five Chinese provinces and municipalities [29].…”